Printer Friendly

GENSIA AND ALLERGAN ENTER INTO RESEARCH AGREEMENT IN OPHTHALMIC DISEASE

GENSIA AND ALLERGAN ENTER INTO RESEARCH AGREEMENT IN OPHTHALMIC DISEASE
 SAN DIEGO, Jan. 30 /PRNewswire/ -- Gensia Pharmaceuticals Inc. (NASDAQ: GNSA) and Allergan Inc. (NYSE: AGN) today announced that the companies have entered into a collaborative agreement under which Allergan will evaluate Gensia's proprietary adenosine regulating agent (ARA) and related technology for the treatment of certain forms of eye disease. Gensia will supply certain of its purine and pyrimidine compounds to Allergan for preclinical research in ophthalmic and other diseases of the eye, according to David F. Hale, Gensia chairman, president and chief executive officer.
 "Based on the anti-inflammatory actions of our ARAs observed in preclinical studies, we believe these compounds may have potential for use in specific ophthalmic indications," said Hale.
 Allergan will perform research involving Gensia's compounds. While Gensia will retain any ownership rights to compounds and developments under the arrangement, the companies will determine plans for commercializing any discoveries which may arise from the research program to be undertaken under the agreement.
 "This research collaboration provides Allergan with access to interesting technologies with potential application for the treatment of diseases of the eye," said William C. Shepard, president and chief executive officer, Allergan Inc.
 Allergan Inc., headquartered in Irvine, Calif., is a global provider of specialty therapeutic products and is now expanding beyond skin care and its leadership position in eye care.
 Gensia Pharmaceuticals is a San Diego-based biopharmaceutical company formed to discover, develop, manufacture and market novel pharmaceutical products for the treatment and diagnosis of human diseases. Gensia currently has two cardiovascular drugs in late-stage clinical trials, Arasine (TM) and arbutamine, part of the GenESA (TM) System. Arasine is the lead compound based on Gensia's ARA technology.
 -0- 1/30/92 R
 /CONTACT: David F. Hale or Martha L. Hough of Gensia Pharmaceuticals, 619-546-8300; or Shel Holtz (media), 714-752-4387, or Jeff D'Eliscu (investors), 714-752-4636, both of Allergan/
 (GNSA AGN) CO: Gensia Pharmaceuticals Inc.; Allergan Inc. ST: California IN: MTC SU: JVN


EH-CH -- SD002 -- 5417 01/30/92 16:09 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 30, 1992
Words:333
Previous Article:SOCIAL SECURITY CLAIMANTS MAY GET BENEFITS AS BAILEY CLASS ACTION IS IMPLEMENTED
Next Article:INVESTMENT COMPANY INSTITUTE REPORTS ON ASSETS OF MONEY MARKET MUTUAL FUNDS
Topics:


Related Articles
GENSIA AND SANDOZ SIGN AGREEMENT FOR DIABETES RESEARCH
GENSIA AND ALLERGAN ENTER INTO RESEARCH AGREEMENT IN OPHTHALMIC DISEASE
CyDex and Allergan Announce the Signing of a CAPTISOL(R) Licensing Agreement.
Cambridge Neuroscience Announces Extension of Allergan Collaboration.
Oculex Pharmaceuticals to Formulate Allergan Compounds Using DDS(R) Technology.
ALLERGAN LICENSES QUINOLONE ANTIBIOTIC FROM KYORIN.
Allergan and EntreMed Announce Strategic Alliance for Eye Diseases; Allergan to Develop EntreMed's Panzem(TM) for Treatment of Ophthalmic Indications...
Oculex Pharmaceuticals Announces Joint Development Agreement With Allergan for EntreMed Compound.
Inspire Pharmaceuticals, Inc. Announces Receipt Of Milestone Payment from Allergan.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters